Rapamycin recruits SIRT2 for FKBP12 deacetylation during mTOR activity modulation in innate immunity
Rapamycin recruits SIRT2 for FKBP12 deacetylation during mTOR activity modulation in innate immunity

Lin Hu,1,7 Fuxian Chen,1,7 Chao Wu,1,7 Jun Wang,2,7 Si-si Chen,3 Xiang-rong Li,1 Jing Wang,1 Linpeng Wu,1 Jian-ping Ding,3 Jian-chuan Wang,4 Chao Huang,1 Hui Zheng,1 Yu Rao,5 Yu Sun,3 Zhijie Chang,5 Wei Deng,6,* Cheng Luo,2,*, and Y. Eugene Chin1,6,*

SUMMARY

The mammalian target of rapamycin (mTOR) is a serine-threonine kinase involved in cellular innate immunity, metabolism, and senescence. FK506-binding protein 12 (FKBP12) inhibits mTOR kinase activity via direct association. The FKBP12-mTOR association can be strengthened by the immunosuppressant rapamycin, but the underlying mechanism remains elusive. We show here that the FKBP12-mTOR association is tightly regulated by an acetylation-deacetylation cycle. FKBP12 is acetylated on the lysine cluster (K45/K48/K53) by CREB-binding protein (CBP) in mammalian cells in response to nutrient treatment. Acetyl-FKBP12 associates with CBP acetylated Rheb. Rapamycin recruits SIRT2 with a high affinity for FKBP12 association and deacetylation. SIRT2-deacetylated FKBP12 then switches its association from Rheb to mTOR. Nutrient-activated mTOR phosphorylates IRF3S386 for the antiviral response. In contrast, rapamycin strengthening FKBP12-mTOR association blocks mTOR antiviral activity by recruiting SIRT2 to deacetylate FKBP12. Hence, on/off mTOR activity in response to environmental nutrients relies on FKBP12 acetylation and deacetylation status in mammalian cells.

INTRODUCTION

Mammalian target of rapamycin (mTOR) is a PI3K/P45 kinase involved in cellular environment in mammalian cells that is activated in response to different stimuli. Nutrient or stress activated mTOR serves as the front line protein kinase for secondary line protein kinases or transcription factors activation, leading to diverse activities, including protein synthesis and gene regulation involved in senescence and innate immunity (Le Sage et al., 2016; Weichhart et al., 2015). In addition to the carboxy-terminal catalytic domain, mTOR bears a number of regulatory domains within its NH2-terminal lobe. In mammalian cells, the mTOR kinase activity is regulated by a number of protein factors forming mTOR complex 1 (mTORC1) or mTOR complex 2 (mTORC2) according to their distinct core components and downstream signaling functions in a number of biological processes (Saxton and Sabatini, 2017). Among the mTORC1 kinase regulators, FK506-binding protein (FKBP) family member FKBP12 is one of the most prominent antagonists inhibiting mTOR catalytic activity (Hoefler et al., 2008; Sabers et al., 1995; Chen et al., 1995). Although FKBP12 is a peptidyl-prolylcis-trans isomerase, inhibition of the enzymatic activity is irrelevant to immunosuppressive action of the drugs that bind to FKBP12 (Tropschug et al., 1990; Siekierka et al., 1989). FKBP12 directly binds to mTOR in the FKBP12-rapamycin binding (FRB) domain, which is adjacent to the catalytic domain of mTOR (Yang et al., 2013). Notably, rapamycin, an immunosuppressant drug, tightly associates with FKBP12 to inhibit mTOR-mediated cell signaling and impedes the growth and activity of immune cells.

mTOR can be activated by the small GTPase Rheb in response to amino acids or nutrient environments (Sancak et al., 2008; Long et al., 2005). Rheb can keep FKBP12 or other FKBP family members such as FKBP38 away and regulates mTOR catalytic activity in a guanosine 5’-triphosphate (GTP)-dependent manner (Bai et al., 2007). Rheb binds to mTOR directly, causing a global conformational change that allosterically reveals active-site residues and accelerates catalysis (Yang et al., 2017). The mTOR signalosome relies overall on serine-threonine phosphorylation for the downstream activation process. Deacetylase inhibitors such as trichostatin A (TSA) or nicotinamide (NAM) have been shown to modulate mTOR activity...
Both Raptor and Rictor, the mTORC1 and mTORC2 components respectively, are under acetylation regulation in response to the cellular environmental changes (Glidden et al., 2012; Son et al., 2019). Since lysine deacetylase members physically interact with mTOR complex and lysine deacetylase inhibitors can modulate mTOR activity (Zhang et al., 2015; Ghosh et al., 2010; Back et al., 2011; Ma et al., 2015), mTOR signalosome activity is most likely under reversible acetylation modulation.

Apart from coordinating cell growth and metabolism with environmental inputs, mTOR has a master regulatory role in the innate immune system (Saemann et al., 2009). Innate immune responses, including antiviral responses, however, involve nuclear transcription regulation events. The presence of rapamycin in the cellular environment, specifically blocks mTOR activity for downstream substrates, such as the phosphorylation and activation of p70S6K and the release of eIF4E inhibition by PHAS-1/4E-BP1, as well as proinflammatory cytokines and type I IFNs involved in innate immune responses (Soliman, 2013; Digomann et al., 2019; Cao et al., 2008). Rapamycin was also demonstrated to impede the poly I:C-stimulated upregulation of INF-β expression in human oral keratinocytes (Zhao et al., 2010). There are some clues that cytoplasmic transcription factors, including MAPK and interferon regulatory factor (IRF) can be activated by mTOR during antiviral responses (Zhao et al., 2010; Fekete et al., 2014). Despite extensive studies, the mechanism by which mTOR regulates antiviral transcription events remains elusive.

Here, we found that FKBP12 and Rheb, the regulators of mTOR activity are precisely regulated by acetylation and deacetylation. CREB-binding protein CBP)-acyetylated FKBP12 and Rheb undergo association. In contrast, only deacetyl-FKBP12 can then associate with mTOR. Both NAM (deacetylase sirtuin family inhibitor) and TSA (deacetylase HDAC family inhibitor) dramatically promote the FKBP12-Rheb association but disrupt the FKBP12-mTOR association. Interestingly, rapamycin can recruit SIRT2 with high affinity, leading to FKBP12 deacetylation. In addition, we demonstrated that nutrient-activated mTOR induces IRF3 serine phosphorylation at S386. We provide evidence that mTOR can promote antiviral response via inducing IRF3 serine phosphorylation, whereas rapamycin blocks mTOR activity in the antiviral response via SIRT2 recruitment and SIRT2-mediated FKBP12 deacetylation.

**RESULTS**

**FKBP12 is acetylated in response to nutrient availability and is involved in regulating cellular viral infection activity**

To investigate the mechanism by which FKBP12 impedes mTOR activity, we examined FKBP12 posttranslational modifications. mTOR was more active in FKBP12-depleted cells in both the presence and absence of rapamycin (Figure S1A), suggesting that mTOR activity can be regulated by endogenous FKBP12. FKBP12 acetylation was detected in the cytoplasmic fraction prepared from mouse fibroblasts that received amino acids or serum treatment (Figure 1A). Overexpression of CBP or its prolig p300 in HEK293T cells induced FKBP12 acetylation (Figure 1B). CBP is mainly a nuclear factor that can be exported from nuclei in response to various stimulations (Tang et al., 2007; Cohen et al., 2004). Nutrient (amino acids and serum) supplementation induced CBP nuclear exportation in HeLa cells (Figure 1C). Given that CBP was the most prominent acetyltransferase in FKBP12 acetylation induction in cytoplasm, we purified CBP-acetylated FKBP12 from HEK293T transfectants for mass spectrometry analysis, and the results showed that three lysine residues (K45, K48, and K53) of the FKBP12 central lysine cluster were acetylated by CBP (Figures 1D and 1B). Specific polyclonal antibodies recognizing acetyl-K48 and acetyl-K53 of FKBP12 were then prepared (Figure S1C). Upon in vitro acetylation with recombinant CBP protein, GST-FKBP12 recombinant protein was recognized by the pan-Ack, acetyl-K48 and acetyl-K53 antibodies (Figure 1E). SGC-CBP30, a selective CBP/p300 bromodomain inhibitor, suppressed FKBP12 acetylation (Figure S1D). These data indicate that FKBP12 is acetylated by CBP both in vitro and in vivo. These lysine residues are highly conserved in the FKBP12 family from different species (Figure 1F). Site-directed mutagenesis of the FKBP12 lysine cluster confirmed that all three conserved lysine residues (K45, K48, and K53) were acetylated by CBP (Figure 1G).

FKBP12 associates with mTOR to restrict its catalytic activity. Therefore, we next tested the effect of KR or KQ mutated FKBP12 on mTOR activity regulation. FKBP12 with the KR mutation, which is a mimic of non-acetylated lysine (KR mutant) largely restricted mTOR activity in S6K1 phosphorylation induction, whereas FKBP12 with the KQ mutation, which is a mimic of acetyl lysine (KQ mutant) became weaker in mTOR activity inhibition than wild-type or KR mutants of FKBP12 (Figure 1H). The time course of serum treatment revealed that FKBP12 acetylation in fibroblasts was induced in 5 min and reached a maximum in.
Figure 1. AA/FBS induces FKBP12 acetylation and involves in regulating cellular viral infection activity
(A) Mouse fibroblasts starved for serum/AA for 24 h followed by AA or FBS treatment (30 min). FKBP12 immunoprecipitates prepared from WCL of these fibroblasts were analyzed in Western blot with pan anti-acetyl-K.
Figure 1. Continued
(B) In HEK293T cells, HA-FKB12 was cotransfected with p300, CBP or Tip60. FKB12 immunoprecipitates were analyzed in Western blot with pan anti-acetyl-K.
(C) Immunofluorescence staining of CBP with anti-CBP. DAPI was used for nuclear counter staining. Scale bar: 20 μm.
(D) Acetyl-FKB12 proteins were purified from HEK293T cells with Flag-FKB12 and HA-CBP cotransfection. Mass spectrometry analysis of trypsinized acetyl-FKB12 proteins uncovered K45, K48, and K53 as the acetyl-residues.
(E) GST-FKB12 recombinant protein was acetylated by CBP in vitro.
(F) Alignment of the K-cluster of FKB12 from different species.
(G) FKB12-K45R, -K48R, and -K53R variants were compared with wild type FKB12 for acetylation induction by CBP in HEK293T cells with HA-FKB12 transfected along with CBP.
(H) HA-FKB12 WT and its mutants were transiently transfected into 293T cells, WCLs were determined with the indicated antibodies.
(I) As indicated, a time course to reveal FBS induced FKB12 acetylation and S6K1 phosphorylation induction in FBS/AA starved mouse fibroblasts. Polyclonal antibodies against FKB12-aK45 and FKB12-aK53 were constructed for FKB12 acetylation analysis. 
(J) WT or FKB12+/− mouse fibroblasts infected with VSV, the infected cells were analyzed by flow cytometry. Left, representative image; right, statistical results of 3 independent experiments. Data are represented as mean ± SD; ***, p < 0.001, two-tailed t test. 
(K) In FKB12+/− mouse fibroblasts, indicated FKB12 KR or KQ variants were overexpressed followed by VSV infection. VSV-G protein was analyzed in Western blot.

To confirm a direct interaction between rapamycin and SIRT2, we tested SIRT2 stability with the compound RC32, which conjugates rapamycin and pomalidomide for FKBP12 degradation (Sun et al., 2019). RC32 caused SIRT2 degradation while depleting FKB12 in HeLa cells (Figure 2C), suggesting a direct association between rapamycin and SIRT2. We also tested whether rapamycin can inhibit mTORC1 signaling after cells were treated with RC32, and the results showed that indeed rapamycin cannot inhibit mTORC1 when cells are treated with RC32 (Figure 2H). We next performed a group of in vitro experiments to verify the binding of rapamycin with SIRT2. Recombinant SIRT2, FKB12, FRB, and HDAC1 proteins purified from bacteria were incubated with rapamycin individually or in combination at different concentrations, and the dissociation constant was determined by isothermal titration calorimetry (ITC) assay and microscale thermophoresis (MST) assay (Figures 2D and 2E). In ITC, the heat transfer during binding is accurately measured to determine the binding constants and other thermodynamic parameters. ITC results showed that the rapamycin and FKB12 binding Kd was 0.24 nM, whereas in the presence of FRB, the FKB12 and rapamycin binding Kd was 0.10 nM, agreeing with previous reports that FKB12 and rapamycin binding Kd.
was 0.2 nM and FKBP12 and rapamycin binding Kd in the presence of FRB was 0.1 nM (Banaszynski et al., 2005; Bayle et al., 2006). The rapamycin and SIRT2 binding Kd was 9.5 nM (Figure 2D). No Kd was fitted from the rapamycin and HDAC1 association, apparently due to their poor, or no, interaction. MST measures the thermophoresis of molecules in a laser-induced temperature gradient. In the MST assay, the rapamycin and SIRT2 binding Kd was 131 nM and the rapamycin and FRB binding Kd was 38.6 nM (Figure 2E). No direct binding was detected between rapamycin and HDAC1, even though rapamycin treatment induced both HDAC1-FKBP12 (Figure S2I, left panel) and SIRT2-FKBP12 associations (Figure S2I, right panel). Although the Kd values measured in these two assays were different, both measurements validated that SIRT2 is a specific substrate of rapamycin. We also incubated rapamycin with purified FKBP12 or HDAC1 alone or together and submitted it to naive polyacrylamide gel electrophoresis (PAGE) for analysis. HDAC1 proteins

Figure 2. SIRT2 deacetylates FKBP12

(A) FKBP12 deacetylation induction by rapamycin in mouse fibroblasts for indicated times and blotted with indicated antibodies.

(B) In HEK293T cells, HA-FKBP12 and FLAG-CBP were cotransfected followed by NAM, or TSA treatment as indicated. Anti-HA IP was analyzed for FKBP12 acetylation with pan acetyl-K antibody in Western blot. FKBP12-acK band intensities were measured by ImageJ software and normalized to FKBP12 (right panel). Data are represented as mean ± SD; ****, p < 0.0001, one-way ANOVA.

(C) HeLa cells were treated with indicated doses of RC32 for 12 h. WCLs were analyzed for SIRT2 or FKBP12 degradation with indicated antibodies.

(D) Rapamycin binding affinity Kds were obtained from ITC analysis of indicated proteins purified from bacteria.

(E) Purified SIRT2, HDAC1, and FRB proteins were incubated with rapamycin for MST analysis.

(F) Naïve PAGE detection of rapamycin ternary complex formation with FKBP12 (left) or with SIRT2 (right). GST-FKBP12, GST-SIRT2 and GST-HDAC1 were purified from bacteria and incubated with rapamycin prior to loading onto the naive PAGE and blotted with anti-GST.
dramatically enhanced rapamycin and FKBP12 association. Under the same conditions used, HDAC1 proteins failed to affect the SIRT2 and rapamycin association (Figure 2F).

**FKBP12 in acetylated and deacetylated states modulates mTOR activity**

Both NAM and TSA treatments elevated S6K1 phosphorylation in fibroblasts (Figure 3A). AA/serum starvation enhanced the FKBP12 and mTOR association in response to rapamycin treatment (Figure S3A). However, both NAM and TSA treatment readily abolished the association of FKBP12 and mTOR in response to rapamycin (Figure 3B). Thus, sirtuin and HDAC family members are involved in modulating the FKBP12-mTOR association and FKBP12 activity even though HDAC family members do not directly interact with rapamycin. Although rapamycin promotes the already effective association between FKBP12 and mTOR, the disruptive effect of NAM or TSA on the FKBP12-mTOR association was confirmed using an optimized mTOR FRB-N-terminal fragment (N-Luc) and C-terminal fragment (C-Luc)-FKBP12 dual element luciferase assay, which was extraordinarily sensitive in characterizing FKBP12 and mTOR association/dissociation in mammalian cells (Figure 3C) (Paulmurugan and Gambhir, 2007). Compared with specific HDAC inhibitors (HDAC1-3 inhibitor CI-994, HDAC1/HDAC2 inhibitor FK-228, HDAC3 inhibitor RGF966, HDAC4/HDAC5 inhibitor LMK225, and HDAC6 inhibitor nexturastat A) (Monneret, 2005), the nonspecific HDAC inhibitor TSA was still the most effective at inhibiting rapamycin-induced FKBP12-mTOR complex formation (Figure S3B), indicating that multiple HDAC family members are capable of deacetylating FKBP12. Structural analysis of the protein-protein interaction between FKBP12 and mTOR revealed that the K45, K48, and K53 residues reside in the interface of the direct association with mTOR (Figure 3D). Among the three residues, K45 of FKBP12 is capable of hydrogen bonding directly with D2102 of mTOR, whereas K48 and K53 can be important in allosteric regulation of FKBP12 conformation required for mTOR interaction in the presence of...
Rheb is also acetylated during nutrient treatment and contributes to mTOR activation

Although Rheb is an important activator of mTORC1, exactly how it stimulates mTORC1 kinase activity remains elusive. Treatment of HEK293T cells with amino acids or serum for up to 30 min induced FKBP12 and Rheb association (Figures 4A and S4A), supporting the previous finding that FKBP12 family members interact with Rheb, the KRAS-like GTPase for mTOR kinase activation during mTORC1 signaling (Bai et al., 2007). Rheb was also acetylated in fibroblasts in response to nutrient supplementation (Figure 4B) and in HEK293T cells by ectopic CBP overexpression (Figure S4B). K8, K121, and K169 residues were identified as acetylation sites on Rheb purified from HEK293T transfectants (Figures 4C and S4C). Rheb was also acetylated by CBP in vitro (Figure S4D). Moreover, the Rheb K8 residue with the “RKX” sequence is species conserved (Figure 4D). “RKX” motifs, i.e., acetyl-“RKS” or acetyl-“RKW” motifs (H3K18: RKQ or H3K79: RKL) in histone H3 N-tail, provide various enzymes or transcription factors for association during epigenetic gene expression regulation (Tang et al., 2007; Fischle et al., 2005). Thus, the central lysine cluster of FKBP12 tightly modulates the FKBP12-mTOR association during rapamycin treatment. NAM or TSA treatment greatly enhanced FKBP12 and Rheb complex formation (Figure 4E), suggesting that acetylation was involved in the interaction between these two proteins. The K45 residue of FKBP12 was involved in the interaction between FKBP12 and Rheb, and FKBP12 with the K45R mutation but not the K45Q mutation reduced its association with Rheb (Figure 4F). We therefore conclude that FKBP12 switches its association between mTOR and Rheb largely depending on its deacetylation or acetylation status. The Rheb-K8R variant reduced Rheb’s interaction with FKBP12, whereas Rheb-K8Q had the opposite effect (Figures 4G and S4E). Equivalently, the Rheb-K8R variant largely abolished mTOR activity in S6K1 phosphorylation, while Rheb-K8Q did not (Figure 4G). In comparison, neither the K121R nor the K169R mutation of Rheb affected mTOR activity or the FKBP12-mTOR association (Figures S4F–S4G), suggesting that Rheb acetylation at K8 residue plays a central role in mTOR activation. In addition, the interaction of Rheb with acetylated FKBP12 seem to be dependent on its nucleotide binding states because GTP loaded Rheb exhibited much higher binding affinity toward acetylated FKBP12 than did GDP loaded or untreated Rheb (Figure S4H).

mTOR phosphorylates IRF3 S386 for INFs induction

mTOR directly regulates IRF3 activity in the antiviral response and IFN production (Bodur et al., 2018; Fekete et al., 2014; Ohman et al., 2015). Rapamycin can facilitate viral replication by regulating mTOR activity (Zhou et al., 2014; Alain et al., 2010). Upon 5 nM rapamycin treatment, VSV infection was elevated in HeLa cells stably overexpressing empty vector and mTOR (Figure 5A), suggesting that rapamycin enhances VSV replication by mTOR. Amino acids or FBS treatment greatly induced IFNα or IFNβ gene expression in HEK293T cells transfected with or without IRF3 (Figures 5B and 5A). Our mass analysis revealed that IRF3 was phosphorylated by mTOR on S386 within the MH2 domain (Figures 5C and 5D). Intriguingly, mTOR preferentially phosphorylates the second serine/threonine residue of those serine/threonine duplicates, such as S386 of S385/S386 of the IRF3-MH2 domain and T37 of T36/T37 and T47 of T46/T47 in the 4EBP factor (Figure 5D). It is worth noting that a supershifting band in the Western blot of IRF3 was observed upon mTOR overexpression, indicating that mTOR might phosphorylate not only S386 but also other sites. Indeed, IRF3 has been reported to be phosphorylated by mTOR at other serine sites (Figure 5C) (Saemann et al., 2009). IRF3-S386 phosphorylation was induced by serum or amino acids treatment in a time-dependent manner (Figures 5E and 5F). Obviously, mTOR not only induced phosphorylation of S6K1 at T389 and 4EBP1 at S65, but also induced IRF3 sphosphorylation at S386 in response to serum treatment (Figure 5F). We confirmed that mTOR phosphorylates IRF3 S386 by in vitro phosphorylation experiment (Figure S5D). In addition, rapamycin treatment inhibited IRF3-S386 phosphorylation in fibroblasts (Figure S5E). Utilizing purified Flag-mTOR protein to incubate with synthesized IRF3-S386 peptide under in vitro kinase assay conditions, IRF3 S386 phosphorylation by mTOR was confirmed by mass spectrometric
In VSV infected cells, IRF3-S386 phosphorylation was induced, reflecting the host cell response to viral infection (Figure 5 H). IRF3-S386 phosphorylation by mTOR was enhanced by cotransfection of IRF3 with Rheb but reduced by cotransfection of IRF3 with FKBP12 (Figure 5 H). IRF3 underwent nuclear translocation when mTOR was overexpressed alone but not when mTOR and FKBP12 were expressed together (Figure 5 I). Moreover, IRF3 S386 phosphorylation induction by mTOR overexpression was elevated by Rheb but inhibited by FKBP12 cotransfection (Figure S5 F). Immunofluorescence experiments showed that Rapamycin treatment blocked pS386-IRF3 nuclear induction and translocation (Figure 5 J).

These results suggest that mTOR is a mediator of gene regulation in both host responses and virus countermeasures.

Figure 4. Acetylated-FKB12 associates with acety-Rheb contributing to mTORC1 kinase activation

(A) HEK293T cells transfected with FLAG-FKB12 and Myc-Rheb followed by AA treatment for indicated times. Anti-Flag IP was analyzed for FKB12 and Rheb interaction in Western blot.

(B) In fibroblasts, 20% FBS treatment for indicated time. WCLs prepared for Rheb IP followed by pan acetyl-K blotting.

(C) Mass spectra of acetyl-K8, acetyl-K169 and acetyl-K120 peptides of Rheb recovered from trypsin digests.

(D) Alignment of double-positive “RK” motif of Rheb of different species with “RK” motifs of histone H3.

(E) HA-FKB12 and Myc-Rheb were cotransfected in HEK293T cells. NAM or TSA treatment for 2 h was tested on FKBP12 and Rheb interaction.

(F) Two reporter system (Rheb-N-Luc and FKB12-C-Luc of WT, K48R or K48Q) were cotransfected and treated with rapamycin treatment for 6 h followed by the luciferase reporter activity analysis. Data are represented as mean ± SD; ****, p < 0.0001, one-way ANOVA.

(G) Flag-Rheb WT or variant (K8P, K8Q) or EV was cotransfected with HA-FKB12 in HEK293T cells. Anti-HA IP was analyzed for FKB12 and Flag-Rheb interaction in Western blot with anti-Flag. WCLs were analyzed for S6K1 phosphorylation with anti-S6K1 pT389.

analysis (Figure 5G). In VSV infected cells, IRF3-S386 phosphorylation was induced, reflecting the host cell response to viral infection (Figure 5H). IRF3-S386 phosphorylation by mTOR was enhanced by cotransfection of IRF3 with Rheb but reduced by cotransfection of IRF3 with FKB12 (Figure 5H). IRF3 underwent nuclear translocation when mTOR was overexpressed alone but not when mTOR and FKB12 were expressed together (Figure 5I). Moreover, IRF3 S386 phosphorylation induction by mTOR overexpression was elevated by Rheb but inhibited by FKB12 cotransfection (Figure 5F). Immunofluorescence experiments showed that Rapamycin treatment blocked p3886-IRF3 nuclear induction and translocation (Figure 5J). These results suggest that mTOR is a mediator of gene regulation in both host responses and virus countermeasures.
Figure 5. IRF3 S386 phosphorylation by mTOR is for antiviral genes expression

(A) The mTOR stable HeLa cell line and control cell line were treated with or without 5 nM Rapamycin for 24 h, then the cells infected with VSV, the infected cells were analyzed by flow cytometry. Left, representative image; right, statistical results of 3 independent experiments. Data are represented as mean \pm SD; **, p < 0.01, two-tailed t test.

(B) HEK293T cells were transfected with or without IRF3 as indicated followed by AA treatment or FBS treatment. RT-PCR was performed to analyze IFNα mRNA expression level. Data are represented as mean \pm SD; ****, p < 0.0001, one-way ANOVA.

(C) IRF3-S386 identified with mass spectrometry. IRF3 was purified from HEK293T cells transfected with IRF3 along with mTOR.

(D) IRF3 S385S386 motif was aligned with T36T37 and T45T46 motifs of 4EBP.

(E) IRF3-pS386

(F) FBS: 0 15 30 60 120 (min)

(G) S386 peptide + mTOR

(H) EV mTOR FKBP12 mTOR + FKBP12

(I) IRF3-YFP DAPI Overlay

(J) (-) FLAG-mTOR FLAG-Rheb FLAG-mTOR + Rapa

**Figure 5. IRF3 S386 phosphorylation by mTOR is for antiviral genes expression**

(A) The mTOR stable HeLa cell line and control cell line were treated with or without 5 nM Rapamycin for 24 h, then the cells infected with VSV, the infected cells were analyzed by flow cytometry. Left, representative image; right, statistical results of 3 independent experiments. Data are represented as mean \pm SD; **, p < 0.01, two-tailed t test. **(B) HEK293T cells were transfected with or without IRF3 as indicated followed by AA treatment or FBS treatment. RT-PCR was performed to analyze IFNα mRNA expression level. Data are represented as mean \pm SD; ****, p < 0.0001, one-way ANOVA. **(C) IRF3 protein S386 phosphorylation identified with mass spectrometry. IRF3 was purified from HEK293T cells transfected with IRF3 along with mTOR. **(D) IRF3 S385S386 motif was aligned with T36T37 and T45T46 motifs of 4EBP.**
Acetyl-mTORC1 complex is required for IRF3 S386 phosphorylation to promote antiviral activity

We next sought to understand the mechanism by which mTORC1 modulates IRF3 for antiviral activity. We first tested the role of IRF3 S386 phosphorylation in gene expression. RT-PCR showed that IRF3-S386 phosphorylation by mTOR was critical in type I IFN gene IFN-β expression induction (Figure 6A). mTOR activity in antiviral gene (ISG54 and ISG56) expression induction was elevated by cotransfecting mTOR with Rheb but restricted by FKBP12 (Figure 6B). IFN-β mRNA levels and ISRE-element luciferase activity were then analyzed by overexpressing mTOR, FKBP12, and Rheb in HEK193T cells. The results of both IFN-β mRNA induction and ISRE-element luciferase reporter activity revealed that IRF3 overexpression, along with mTOR enhanced IRF3 transcriptional activity (Figures S6A and S6B).

The antiviral response of the FKBP12-mTOR route was also analyzed in human 2fTGH fibroblasts. The viral gene products UL46 and ICP27 of herpes simplex virus (HSV) and VSV-G of VSV were all elevated when FKBP12 was cotransfected along with mTOR and IRF3 (Figure S6C). FKBP12 with the KQ mutation but not the KR mutation of the lysine cluster largely abolished viral mRNA expression (Figure 6C). As expected, viral infection induced FKBP12 acetylation on the K53 residue in fibroblasts (Figure 6D). In FKBP12+/− cells infected with VSV or HSV, the viral gene product VSV-G protein or UL42 protein was undetectable (Figures 6E and S6D). Consequently, the virus was highly duplicated in wild-type cells but not in FKBP12+/− cells (Figure 6F). HSV is a large nuclear-replicating DNA virus, which activates PI3K (Prejean et al., 2001). Most notably, HSV degraded IFN-β, but not cGAS or STING, in line with prior reports, and this occurred irrespective of US3 activity (Kalamvoki and Roizman, 2014). The SIRT2 inhibitor AGK2 dramatically blocked VSV infection in fibroblasts (Figures 6G and S6E). Acetylation of FKBP12 blocked viral proliferation, whereas deacetylated FKBP12 supported viral proliferation by blocking mTOR activity during innate immunity induction. Taken together, the FKBP12-mTOR forms the deacetyl-mTORC1 complex activity in the presence of SIRT/HDAC deacetylases promote viral replication in cells, whereas Rheb-FKBP12 forms acetyl-mTORC1 complex activity in the presence of CBP prevents viral replication in cells, consistent with their actions within a common pathway in response to viral stress.

Given that HAT and deacetylases are essential components of mTOR signalosome, mTOR activity is under reversible acetylation modulation in cells (Figure 7).

DISCUSSION

The catalytic activity of mTOR in serine/threonine phosphorylation is under tight enzymatic regulation by forming an mTORC1 complex with small protein enzymes, including FKBP12 and Rheb. To keep mTOR in an active form, FKBP12 and Rheb need to recruit the acetyltransferase CBP for acetylation induction. In contrast, FKBP12 recruits deacetylase to maintain its deacetylation status to inhibit mTORC1 complex activity. Acetyl-Rheb attenuates the negative effect of FKBP12 by associating with acetyl-FKB12. Lysine acetyltransferase (KAT) and lysine deacetylase (KDAC) complexes are involved in mTORC1 and mTORC2 complex activity regulation (Ma et al., 2015; Wan et al., 2017). Raptor is acetylated by EP300 on the K1097 residue. Decreased acetyl-raptor inhibits mTORC1 and EP300 activity in fasted mouse tissues during mTORC1 regulation by Leu metabolism (Lundby et al., 2012; Son et al., 2019). TSC2 in its acetylated state is linked to ubiquitin ligation and degradation, leading to mTORC1 activation and cell proliferation. TSC2 deacetylation is suspected to induce autophagy (Garcia-Martinez and Alessi, 2008). Intriguingly,
we showed that SIRT2 and HDAC1 are recruited by rapamycin and FKBP12, respectively, leading to FKBP12 deacetylation. The FKBP12 acetylation event is a precise regulation process in control mTORC1 signaling. This process is in a dynamic equilibrium, in which acetylation and deacetylation reactions occur continuously, generating a steady-state level of FKBP12. Rapamycin preferentially associates with the beta sheet loop of FKBP12 (Liang et al., 1999). SIRT2 is helical overall in structure, which is highly homologous to that of the FRB domain involved in association with rapamycin-FKBP12 (Finnin et al., 2001). However, the underlying mechanisms still need to be further explored. In contrast, in the absence of rapamycin, KAT, such as CBP/p300, acetylates FKBP12 and Rheb to form a catalytically active acetyl-mTOR1 complex.

The interface of FKBP12 for interaction with mTOR bears this conserved lysine cluster, which is now acetylation–deacetylation dependent for its conformational change. Lysine cluster acetylation does not affect its rapamycin association. Ras homolog enriched in brain (Rheb) GTPase directly interacts with mTOR in GTP-bound form and strongly stimulates its kinase activity. Although Rheb may not be directly involved in the AAs-sensing mechanism of mTORC1, it is absolutely required for mTORC1 activation by AAs (Jewell et al., 2013; Sancak et al., 2008). In Rheb knockdown cells, AAs are ineffective in stimulating mTORC1 (Hall et al., 2007). Conversely, mTORC1 is active in cells overexpressing constitutively active or wild-type Rheb, which has much higher basal GTP binding than other GTPases, such as Ras, even under AA starvation, suggesting that Rheb acts either downstream or parallel to AA (Saucedo et al., 2003). We showed here that Rheb bound with more affinity to acetylated FKBP12 than to nonacetylated FKBP12 after the addition of AA, whereas dissociated from nonacetylated FKBP12 without AA
or rapamycin treatment. The mechanism for the differential binding affinity of Rheb to acetylated or non-acetylated FKBP12 is currently unknown; however, it may involve different statuses of Rheb that bind GTP or GDP.

Viruses can utilize host cell intrinsic machinery for replication and trigger cell intrinsic stress responses that restrict viral reproduction (Goubau et al., 2013; Meade et al., 2018). The acetyl-mTORC1 complex and deacetyl-mTORC1 complex represent two different statuses of the mTORC1 complex in cells in response to environmental stresses. As such, viruses counter cytosolic sensing through a unique strategy of directly targeting and dysregulating the mTORC1 complex. Therefore, CBP is involved in mTORC1 complex formation, leading to mTOR activation. In contrast, HDAC1 and SIRT2 are involved in deacetyl-mTORC1 complex formation, leading to mTOR activity shutdown. Although the formation of a tripartite S6K1-STING-TBK1 complex was previously reported for the activation of IRF3 (Wang et al., 2016), short-term rapamycin treatment produced profound inhibition of mTOR-dependent gene expression activities, correlating with a pro-viral response (Meade et al., 2018). We found that mTOR induced an antiviral response directly via IRF3-S386 phosphorylation. Thus, rapamycin-SIRT2 promoted FKBP12-mTOR association and disrupted IRF3 activation by mTOR for the antiviral response.

Limitations of the study
This study demonstrated that mTORC1 activity relies on FKBP12 acetylation and deacetylation status in response to growth signals. In addition, activated mTOR phosphorylates IRF3 S386 for the antiviral response. The questions such as (1) which specific growth signals stimulate the acetylation of FKBP12, (2) how acetyl-FKBP12 associates with acetylated Rheb to regulate mTORC1 activity precisely, and (3) whether the phosphorylation of IRF3 S386 site by mTOC1 may be interfered by TBK1 in physiological condition remain to be investigated in the future.

STAR METHODS
Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Cell line

Figure 7. Illustration of Rapamycin-SIRT2 dependent FKBP12-mTOR inactivation in innate immunity
FKBP12 can be acetylated in cells in the presence of nutrients. Rapamycin recruits SIRT2 but not HDAC1 to deacetylate FKBP12, which can then associate with mTOR. Acetyl-FKBP12 however associates with acetyl-Rheb to form a moderate mTOR activator. mTOR activated IRF3 undergoes nuclear translocation and gene activation leading to anti-viral response, which can be restricted by rapamycin treatment.
METHOD DETAILS
- Cell culture
- Co-immunoprecipitation (IP) and western blotting
- Protein purification
- Total RNA isolation and quantitative real-time PCR
- Luciferase reporter assay
- In vitro kinase assay
- In vitro acetylation assay
- HPLC-MS/MS
- ITC measurements
- Microscale thermophoresis assay
- Immunofluorescence

QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.103177.

ACKNOWLEDGMENTS
The authors thank Xin-yuan Fu, Chun-Fu Zheng, Maruthi Prasad, and Jing-song Gao for helpful suggestions and critical comments and discussions; Xin Chen and Song Hu for technical assistances. This work was supported by National Natural Science Foundation of China Grants 81820108023, 82030077, 2016YFC1302402 and 2018YFC1705500 to Y.E.C; National Natural Science Foundation of China Grant 81902977 to L.H.; and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

AUTHOR CONTRIBUTIONS
Y.E.C., W.D., L.H., and Z.J.C. designed the experiments. F.X.C., C.W., S.S.C., C.H., and L.H. performed IF, COIP, transfections, and WB studies. C.L., J.W., C.S.W., and W.D. performed I.T.C.; C.W., and H.Z. performed IRF3 activity analysis in antivirus; C.W., X.R.L., L.P.W, J.W., and G.Q.X. performed mass spectrometry studies, mutagenesis analysis, and antibody preparation; J.P.D. and J.C.W. performed protein structural analysis; Y.E.C., W.D., L.H., and Z.J.C. wrote the manuscript. All authors read and edited the manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.

Received: May 26, 2020
Revised: August 17, 2021
Accepted: September 23, 2021
Published: November 19, 2021

REFERENCES
Alain, T., Liu, X., Martineau, Y., Sean, P., Pulendran, B., Petroulakis, E., Zemp, F.J., Lemay, C.G., Roy, D., Bell, J.C., et al. (2010). Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc. Natl. Acad. Sci. U S A 107, 1576–1581.
Back, J.H., Rezvani, H.R., Zhu, Y., Guyonnet-Duperat, V., Athar, M., Ratner, D., and Kim, A.L. (2011). Cancer cell survival following DNA damage-mediated premature senescence is regulated by mammalian target of rapamycin (mTOR)-dependent inhibition of sirtuin 1. J. Biol. Chem. 286, 19100–19108.
Bai, X., Ma, D., Liu, A., Shen, X., Wang, Q.J., Liu, Y., and Jiang, Y. (2007). Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 318, 977–980.
Banaszynski, L.A., Liu, C.W., and Wandless, T.J. (2005). Characterization of the FKBP rapamycin FRB ternary complex. J. Am. Chem. Soc. 127, 4715–4721.
Bayle, J.H., Grimley, J.S., Stankunas, K., Gestwicki, J.E., Wandless, T.J., and Crabtree, G.R. (2006). Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity. Chem. Biol. 13, 99–107.
Bergallo, M., Costa, C., Terlizzi, M.E., Margio, S., Sidoti, F., Astegiano, S., Sinesi, F., and Cavallo, R. (2008). Reverse transcriptase-polymerase chain reaction to evaluate human cytomegalovirus lytic gene expression. Mol. Biotechnol. 40, 144–150.
Bodur, C., Kazyken, D., Huang, K., Ekim Ustunel, B., Siroky, K.A., Tooley, A.S., Gonzalez, I.E., Foley, D.H., Acosta-Jaquez, H.A., Barnes, T.M., et al. (2018). The IKK-related kinase TBK1 activates mTORC1 directly in response to growth factors and innate immune agonists. EMBO J. 37, 19–38.
Cao, W., Manicassamy, S., Tang, H., kasturi, S.P., Pirani, A., Murthy, N., and Pulendran, B. (2008). Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat. Immunol. 9, 1157–1164.
H3 methylation and phosphorylation. Nature Regulation of HP1-chromatin binding by histone
Hunt, D.F., Funabiki, H., and Allis, C.D. (2005). Ueberheide, B.M., Garcia, B.A., Shabanowitz, J.,
Fischle, W., Tseng, B.S., Dormann, H.L., SIRT2. Nat. Struct. Biol.
96
dendritic cells is controlled by the immune response in human conventional
Koncz, G., and Rajnavolgyi, E. (2014). The antiviral Fekete, T., Pazmandi, K., Szabo, A., Bacsi, A.,
Digomann, D., Linge, A., and Dubrovska, A. (2013). Cytosolic sensing of viruses. Immunity
287
phosphorylation of Akt protein. J. Biol. Chem.
15
radioresistance: a link confirmed. Autophagy
Kessler, B.M., and Sinclair, D.A. (2004). Imahiyerobo, T.A., Miller, C., Frye, R., Ploegh, H., Kessler, B.M., and Sinclair, D.A. (2004). (2008). Removal of FKBP12 enhances mTOR.
Raptor interactions, LTP, memory, and perseverative/repetitive behavior. Neuron 60, 832–845.
Hong, S., Zhao, B., Lombard, D.B., Fingar, D.C., and Inoki, K. (2014). Cross-talk between sirtuin and mammalian target of rapamycin complex 1 (mTORC1) signaling in the regulation of S6 kinase
1 (S6K1) phosphorylation. J. Biol. Chem. 289, 13132–13141.
Jewell, J.L., Russell, R.C., and Guan, K.L. (2013). Amino acid signaling upstream of mTOR. Nat. Rev. Mol. Cell Biol. 14, 133–139.
Kalamvoki, M., and Rozman, B. (2014). HSV-1 degrades, stabilizes, requires, or is stung by STING depending on ICP0, the US3 protein kinase, and cell derivation. Proc. Natl. Acad. Sci. U S A 111, E611–E617.
Le Sage, V., Cinti, A., Amorim, R., and Mouland, A.J. (2016). Adapting the stress response: viral subversion of the mTOR signaling pathway. Viruses 8, 152.
Liang, J., Choi, J., and Clardy, J. (1999). Defined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution. Acta Crystallogr. D Biol. Crystallogr. 55, 736–744.
Long, X., Un, Y., Ortiz-Vega, S., Yonezawa, K., and Avruch, J. (2005). Rheb binds and regulates the mTOR kinase. Curr. Biol. 15, 702–713.
Lundby, A., Lage, K., Weinert, B.T., Bekker-Jensen, D.B., Secher, A., Skovgaard, T., Kelstrup, C.D., Dmytryshyn, M., Lundby, C., and Olsen, J.V. (2012). Proteomic analysis of lysine acetylation sites in rat tissues reveals organ specificity and subcellular patterns. Cell Rep. 2, 419–431.
Ma, L., Tang, H., Yin, Y., Yu, R., Zhao, J., Li, Y., Mulholland, M.W., and Zhang, W. (2015). HDAC5: mTORC1 interaction in differential regulation of ghrelin and nucleobindin 2 (NUCB2)/nesfatin-1. Mol. Endocrinol. 29, 1571–1580.
Mead, N., Furey, C., Li, H., Verma, R., Chai, Q., Rollois, M.G., DIGIUSEPPE, S., Naghavi, M.H., and Walsh, D. (2018). Poxviruses evade cytosolic sensing through disruption of an mTORC1–mTORC2 regulatory circuit. Cell 174, 1143–1157.e17.
Monneret, C. (2005). Histone deacetylase inhibitors. Eur. J. Med. Chem. 40, 1–13.
Ohman, T., Soderholm, S., Paidikondala, M., Lietzen, N., Matikainen, S., and Nyman, T.A. (2015). Phosphoproteomic characterization reveals that Sendai virus infection activates mTOR signaling in human epithelial cells. Proteomics 15, 2087–2097.
Paulmurugan, R., and Gambhir, S.S. (2007). Combinatorial library screening for developing an improved split-firefly luciferase fragment-assisted complementation system for studying protein–protein interactions. Anal. Chem. 79, 2346–2353.
Prejean, C., Sarma, T., Kurnasov, O., Usacheva, A., Hemmings, B., Cantley, L., Fruman, D.A., Morrison, L.A., Buller, R.M., and Colacino, O.M. (2001). Phosphatidylinositol 3-kinase confers resistance to encephalomyocarditis and herpes simplex virus-induced cell death through the activation of distinct downstream effectors. J. Immunol. 167, 4553–4559.
Sabers, C.J., Martin, M.M., Brunn, G.J., Williams, J.M., Dumont, F.J., Wiederecht, G., and Abraham, R.T. (1995). Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem. 270, 815–822.
Saemen, M.D., Haidinger, M., Hecking, M., Horl, W.H., and Weichhart, T. (2009). The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am. J. Transpl. 9, 2655–2661.
Sancak, Y., Peterson, T.R., Shaul, Y.D., Lindquist, R.A., thoreen, C.C., Bar-Peled, L., and Sabatini, D.M. (2008). The Rag GTPases bind rapamid and mediate amino acid signaling to mTORC1. Science 320, 1496–1501.
Saucedo, L.J., Gao, X., Chiarelli, D.A., Li, L., Pan, D., and Edgar, B.A. (2003). Rheb promotes cell growth as a component of the insulin/ TOR signaling network. Nat. Cell Biol. 5, 566–571.
Saxton, R.A., and Sabatini, D.M. (2017). mTOR signaling in growth, metabolism, and disease. Cell 169, 361–371.
Siekierka, J.J., Hung, S.H., Poe, M., Lin, C.S., and Sigal, N.H. (1989). A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 341, 755–757.
Soares da Costa, T.P., Desbois, S., Dogovski, C., Gorman, M.A., Ketaren, N.E., Paxman, J.J., Siddiqui, T., Zammitt, L.M., Abbott, B.M., Robins-Browne, R.M., et al. (2016). Structural determinants defining the allosteric inhibition of an essential antibiotic target. Structure 24, 1282–1291.
Soliman, G.A. (2013). The role of mechanistic target of rapamycin (mTOR) complexes in signaling the immune responses. Nutrients 5, 2231–2257.
Son, S.M., Park, S.J., Lee, H., Siddiqui, F., Lee, J.E., Menzies, F.M., and Rubinstein, D.C. (2019). Leucine signals to mTORC1 via its metabolite acetyl-coenzyme A. Cell Metab. 29, 192–201.e7.
Sun, X., Wang, J., Yao, X., Zheng, W., Yao, Y., Lan, T., Wang, L., Sun, Y., Zhang, X., Zhao, Q., et al. (2019). A chemical approach for global protein knockdown from mice to non-human primates. Cell Discov. 5, 10.
Tang, X., GAO, J.S., Guan, Y.J., McLane, K.E., Yuan, Z.L., Ramatram, B., and Chin, Y.E. (2007). Acetylation-dependent signal transduction for type I interferon receptor. Cell 131, 93–105.
Tropschug, M., Wachter, E., Mayer, S., Schönbrunner, E.R., and Schmid, F.X. (1990). Isolation and sequence of an FK506-binding protein from N. crassa which catalyzes protein folding. Nature 346, 674–677.
Wan, W., You, Z., Xu, Y., Zhou, L., Guan, Z., Peng, C., Wang, C.L., Su, H., Zhou, T., Xia, H., and Liu, W. (2017). mTORC1 phosphorylates acetyltransferase p300 to regulate autophagy and Lipogenesis. Mol. Cell 68, 323–335.e6.
Wang, F., Alain, T., Szretter, K.J., Stephenson, K., Pol, J.G., Atherton, M.J., Hoang, H.D., Forseca, B., Zakaria, C., Chen, L., and Rangwala, Z. (2016). S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3. Nat. Immunol. 17, 514–522.
Weichhart, T., Hengstschlager, M., and Linke, M. (2015). Regulation of innate immune cell function by mTOR. Nat. Rev. Immunol. 15, 599–614.

Yang, H., Jiang, X., Li, B., Yang, H.J., Miller, M., Yang, A., Dhar, A., and Pavletich, N.P. (2017). Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40. Nature 552, 368–373.

Yang, H., Rudge, D.G., Koos, J.D., Vaidialingam, B., Yang, H.J., and Pavletich, N.P. (2013). mTOR kinase structure, mechanism and regulation. Nature 497, 217–223.

Ye, C., Wu, J., Tong, W., Shan, T., Cheng, X., Xu, J., Liang, C., Zheng, H., Li, G., and Tong, G. (2018). Comparative genomic analyses of a virulent pseudorabies virus and a series of its in vitro passaged strains. Virol. J. 15, 195.

Zhang, J., Ng, S., Wang, J., Zhou, J., Tan, S.H., Yang, N., Lin, Q., Xia, D., and Shen, H.M. (2015). Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways. Autophagy 11, 629–642.

Zhao, J., Benakanakere, M.R., Hosur, K.B., Galicia, J.C., Martin, M., and Kinane, D.F. (2010). Mammalian target of rapamycin (mTOR) regulates TLR3 induced cytokines in human oral keratinocytes. Mol. Immunol. 48, 294–304.

Zhou, X., Wang, Y., Metselaar, H.J., Janssen, H.L., Peppelenbosch, M.P., and Pan, Q. (2014). Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. J. Hepatol. 61, 746-754.

Zhou, Y., Ren, Y., Cong, Y., Mu, Y., Yin, R., and Ding, Z. (2017). Autophagy induced by bovine viral diarrhea virus infection counteracts apoptosis and innate immune activation. Arch. Virol. 162, 3103–3118.
## STAR METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| Anti-lys-48 FKBP12   | This paper | N/A        |
| Anti-lys-53 FKBP12   | This paper | N/A        |
| anti-FKB12          | Santa Cruz | CAT:sc-133067, RRID:AB_2102847 |
| anti-Myc            | Santa Cruz | CAT: sc-40, RRID:AB_2857941 |
| anti-HA             | Santa Cruz | CAT: sc-7392 |
| anti-phosphoS6K Thr389 | Cell Signaling Technology | CAT#92345, RRID:AB_2269803 |
| anti-S6K            | Cell Signaling Technology | CAT#9202S, RRID:AB_331676 |
| anti-phospho-4E-BP1 Thr70 | Cell Signaling Technology | CAT#9455, RRID:AB_330949 |
| anti-4E-BP1         | Cell Signaling Technology | CAT#9452S, RRID:AB_331692 |
| anti-phospho-AKT 5473 | Cell Signaling Technology | CAT#4060S, RRID:AB_2315049 |
| anti-AKT            | Cell Signaling Technology | CAT#9272S, RRID:AB_329827 |
| anti-phospho-PKC S657 | Abcam | CAT#ab180848, RRID:AB_2783796 |
| Anti-PKC            | Cell Signaling Technology | CAT#2056T, RRID:AB_2284227 |
| anti-Acetylated-Lysine | Cell Signaling Technology | CAT#9441L, RRID:AB_331805 |
| anti-IRF3           | Cell Signaling Technology | CAT#4302S, RRID:AB_1904043 |
| anti-phosphoRF3 Ser386 | Cell Signaling Technology | CAT#37829S, RRID:AB_2799121 |
| anti-CBP            | Cell Signaling Technology | CAT#7389S, RRID:AB_2616020 |
| anti-VSVG           | Cell Signaling Technology | CAT#814545 |
| Anti-UL42           | Abcam | CAT#ab19298, RRID:AB_444839 |
| M2-conjugated magnetic beads | Sigma | CAT#A2220, RRID:AB_10963035 |
| anti-Flag antibodies | Sigma | CAT#F1804, RRID:AB_262044 |
| Anti-rabbit IgG (H+L) (DyLight™ 680 Conjugate) | Cell Signaling Technology | CAT#5366, RRID:AB_10693812 |
| Anti-mouse IgG (H+L) (DyLight™ 800 Conjugate) | Cell Signaling Technology | CAT#5257, RRID:AB_10693543 |
| Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 | Introvigen | CAT#A11029, RRID:AB_2534088 |
| Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 633 | Introvigen | CAT#A21070, RRID:AB_2535731 |
| **Bacterial and virus strains** |        |            |
| BL21                | Vazyme | CAT: C504-02 |
| VSV-GFP             | Dr. Hui Zheng Lab | N/A |
| HSV                 | Dr. Hui Zheng Lab | N/A |
| **Chemicals, peptides, and recombinant proteins** |        |            |
| Rapamycin           | Selleck | S1039 |
| NAM                 | Selleck | S1899 |
| TSA                 | Selleck | S1045 |
| RC32                | (Sun et al., 2019) | N/A |
| CI-994              | Selleck | S2818 |
| FK228               | Selleck | S3020 |
| RGF966              | Selleck | S7229 |
| LMK225              | Selleck | S7569 |
| Nexturastat A       | Selleck | S7473 |

(Continued on next page)
## REAGENT or RESOURCE SOURCE IDENTIFIER

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| AGK2                | Selleck | S7577      |
| Nickel-agarose beads| Thermo Scientific | CAT: #88221 |
| Immobilized Glutathione | Thermo Scientific | CAT: #15160 |
| Lyso-Tracker Red    | KeyGEN Biotech   | CAT: KGMP006 |
| ProLong™ Gold       | Thermo Scientific | CAT: P10144 |
| IRF3 peptide        | This paper      | N/A        |
| Recombinant SIRT2 protein | This paper      | N/A        |
| Recombinant FKBP12 protein | This paper      | N/A        |
| Recombinant FRB protein | This paper      | N/A        |
| Recombinant HDAC1 protein | This paper      | N/A        |
| Recombinant IRF3 protein | This paper      | N/A        |

### Experimental models: cell lines

| cell lines | SOURCE | RRID |
|------------|--------|------|
| A549       | ATCC   | RRID:CCL-185 |
| HEK293T    | ATCC   | RRID:CRL-11268 |
| MEF        | Dr. Hui Zheng Lab | N/A |
| Hela       | ATCC   | RRID:CCL-2 |

### Recombinant DNA

| DNA            | SOURCE | IDENTIFIER |
|----------------|--------|------------|
| Flag-FKBP12    | This paper      | N/A        |
| HA-FKBP12-K45R | This paper      | N/A        |
| HA-FKBP12-K48R | This paper      | N/A        |
| HA-FKBP12-K48Q | This paper      | N/A        |
| HA-FKBP12-K53R | This paper      | N/A        |
| HA-FKBP12-K53Q | This paper      | N/A        |
| HA-FKBP12     | This paper      | N/A        |
| Myc-FKBP12    | This paper      | N/A        |
| Myc-Rheb      | This paper      | N/A        |
| Flag-Rheb     | This paper      | N/A        |
| Flag-Rheb-K8R | This paper      | N/A        |
| Flag-Rheb-K8Q | This paper      | N/A        |
| Flag-Rheb-K121R | This paper     | N/A        |
| Flag-Rheb-K121Q | This paper     | N/A        |
| Flag-mTOR     | This paper      | N/A        |
| Myc-mTOR      | This paper      | N/A        |
| mTOR-N-Luc    | This paper      | N/A        |
| FKB12-C-Luc   | This paper      | N/A        |
| FKB12-C-Luc-K45R | This paper   | N/A        |
| FKB12-C-Luc-K45Q | This paper   | N/A        |
| FKB12-C-Luc-E108A | This paper | N/A        |
| Rheb-N-Luc    | This paper      | N/A        |
| Rheb-N-Luc-K8R | This paper      | N/A        |
| Rheb-N-Luc-K8Q | This paper      | N/A        |
| Rheb-N-Luc-K169R | This paper   | N/A        |
| Rheb-N-Luc-K169Q | This paper   | N/A        |
| HA-CBP        | This paper      | N/A        |
| CBP           | This paper      | N/A        |

(Continued on next page)
RESOURCE AVAILABILITY

**Lead contact**
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Y. Eugene Chin (chinyue@suda.edu.cn).

**Materials availability**
All unique reagents generated in this study are available from the Lead Contact with a completed Material Transfer Agreement.

### REAGENT or RESOURCE SOURCE IDENTIFIER

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| HA-P300             | This paper | N/A |
| Myc-Tip60           | This paper | N/A |
| Flag-Sirt2          | This paper | N/A |
| Flag-Sirt2: H187Y   | This paper | N/A |
| ISRE-Luc            | This paper | N/A |
| Flag-IRF3           | This paper | N/A |
| HA-Raptor           | Dr. Jiahuai Han Lab | N/A |

### Oligonucleotides

| ORF | SOURCE | IDENTIFIER |
|-----|--------|------------|
| shRNA | Santa Cruz | CAT: sc-35378-SH |
| IFN-α Forward: 5'-gtgagaaatatctccacagact-3' | (Zhou et al., 2017) | N/A |
| Reverse: 5'-tgaggaggagaagctgctcatga-3' | |
| IFN-β sequencing Forward: 5'-cattaccttggaagcagga-3' | This paper | N/A |
| Reverse: 5'-cagctactgcgtgtaagac-3' | |
| ISG54 Forward: 5'-cactctggagtgaatagc-3' | This paper | N/A |
| Reverse: 5'-gtcagattcagcgaatgg-3' | |
| ISG56 Forward: 5'-tcagcgcaccatgag-3' | This paper | N/A |
| Reverse: 5'-tcaggtgagaagtgg-3' | |
| UL46 Forward: 5'-gcacccgctgaagcaac -3' | (Ye et al., 2018) | N/A |
| Reverse: 5'-cactggtttctatgag-3' | |
| ICP27 Forward: 5'-cggctactcagctgcagta-3' | (Bergallo et al., 2008) | N/A |
| Reverse: 5'-agcaccagctgcaagacact -3' | |
| VSV Forward: 5'-agccgcgtatctcatgctga-3' | This paper | N/A |
| Reverse: 5'-ctcggcttcgacagcaggt-3' | |
| GAPDH Forward: 5'-tcgacagctgcggcaatct-3' | This paper | N/A |
| Reverse: 5'-ccggttgaacctggacactc-3' | |

### Software and algorithms

| SOFTWARE or ALGORITHM | SOURCE | URL |
|-----------------------|--------|-----|
| Prism                 | graphpad | https://www.graphpad.com/ |
| Flowjo                | NIH    | https://imagej.nih.gov/ij/ |
| Image J               | NIH    | https://imagej.net |

**OPEN ACCESS**
**Data and code availability**

All data reported in this paper will be shared by the lead contact upon request.

This paper does not report original code.

Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

**Cell line**

The following cell line were used in the study

1. Human 293T Cell line (RRID: CRL-11268)

   Origin: Human embryonic kidney tissue

   Culture media and conditions: 293T cells were obtained from ATCC and were cultured in Dulbecco’s Modified Eagle’s Medium with 10% fetal bovine serum (EallBio, 03.U16001DC), penicillin (100 U/ml), and streptomycin (100 mg/ml) in a humidified 5% CO₂ incubator at 37°C. We did not authenticate this cell line in our laboratory.

2. A549 Cell line (RRID: CCL-185)

   Origin: Human lung carcinoma cell line obtained from a 58-year-old male.

   Culture media and conditions: A549 cells were obtained from ATCC and were cultured in Dulbecco’s Modified Eagle’s Medium with 10% fetal bovine serum (EallBio, 03.U16001DC), penicillin (100 U/ml), and streptomycin (100 mg/ml) in a humidified 5% CO₂ incubator at 37°C. We did not authenticate this cell line in our laboratory.

3. Hela Cell line (RRID: CCL-2)

   Origin: Human cervix adenocarcinoma cell line obtained from a 31-year-old female.

   Culture media and conditions: Hela cells were obtained from ATCC and were cultured in Dulbecco’s Modified Eagle’s Medium with 10% fetal bovine serum (EallBio, 03.U16001DC), penicillin (100 U/ml), and streptomycin (100 mg/ml) in a humidified 5% CO₂ incubator at 37°C. We did not authenticate this cell line in our laboratory.

4. FKBP12-/- MEFs

   Stable cell lines with ectopic expression of FKBP12 and its mutants were established by lentivirus transduction.

**METHOD DETAILS**

**Cell culture**

Amino acids starvation based method as being described. Briefly, cells were washed with PBS (Hyclone, SH30256.01B) and transferred into the prepared EBSS medium (Solabio, H2020) for 3 hrs.

HEK293T and HeLa cells were transfected with polyethyleneimine (Mr 40,000; Polysciences) or Lipofectamine 2000 (Invitrogen, 11668019) according to the manufacturers’ instructions. For production of lentiviral supernatants, HEK293T cells were cotransfected with the indicated lentiviral vectors together with helper plasmids using polyethyleneimine. Viral stocks were prepared by collecting the medium 48 hrs after transfection.

Stable cell lines with ectopic expression of FKBP12 and its mutants were established by lentivirus transduction. FKBP12/- MEFs were infected with virus in the presence of polybrene (8 µg/ml). Twenty-four hrs after infection, media were changed to fresh medium containing 1 µg/ml puromycin. Five days later, the GFP positive cells were sorted for further experiments.
Co-immunoprecipitation (IP) and western blotting

Cells were treated or transfected as indicated in the figure legends and washed once with cold PBS. Cells were lysed in lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% NP-40, 10% glycerol, 1 mM DTT and complete protease inhibitor cocktail) for 15 min on ice and centrifuged at 20,000 g for 10 min. Protein was measured in the supernatants, and equal amounts of protein were processed for IP. For IP of endogenous FKBP12, 2 μg specific antibodies were routinely added into the soluble fraction, and rotated for 1 hr at 4°C. 20 μl of a 50% slurry of protein A/G-beads (Thermo Scientific, 20241) was incubated with soluble proteins overnight at 4°C. Immunoprecipitates were washed with PBS 3 times and subjected to western blotting with specific antibodies for analysis. For tag-protein IP, 5 μl of a 50% slurry of beads was used for each sample.

The prepared protein add 5×SDS and boil for 10 minutes at 95°C, then samples were separated by using SDS-PAGE, transferred onto PVDF membranes and incubated with the corresponding antibodies. The bands were analyzed using Odyssey Infrared Imaging System.

Protein purification

GST-tagged SIRT2, HDAC1, mTOR (2011-2144 aa), FKBP12, and His-tagged FKBP12, Rheb were expressed in E.coli strain BL21 (C504-02) by induction with 0.1 mM isopropyl β-D-thiogalactoside for 12 h at 16°C. His-tagged proteins and GST-tagged proteins were purified using nickel-agarose beads and glutathione Sepharose beads, respectively, according to the manufacturers’ instructions. Flag-tagged FKBP12, Rheb, and IFR3 were transiently expressed in HEK293T cells for 36 hrs and purified using anti-Flag M2 magnetic beads (Sigma, M8823) according to the manufacturer’s instructions. Purified proteins were added to a final concentration of 10% glycerol and stored at -80°C.

Total RNA isolation and quantitative real-time PCR

Total RNAs were extracted using TRIzol (TIANGEN, DP-405-02) according to the manufacturer’s instructions. Total RNA (2 μg) was reverse transcribed using Prime Script RT reagent kit (TaKaRa, RR036A). Quantitative RT-PCR was carried out using SYBR green (Bimake, B21203) and ABI Step One Plus real-time PCR system (Applied Biosystems).

Luciferase reporter assay

The dual-element reporter assay system was performed based on a previously described method (Paulmurugan and Gambhir, 2007). Briefly, FKBP12 was fused to C-luc, and FRB or Rheb was fused to N-luc. Rapamycin was added to induce the approaching and reconstitution of split luciferase. HEK293T cells were transfected in triplicate with 100 ng of firefly luciferase reporter plasmids and 10 ng of sea pansy luciferase reporter plasmids (pTK-RL) using polyethylenimine in 24-well plates. Twenty four hours after transfection, cells were harvested and collected to measure firefly and sea pansy luciferase activities.

In vitro kinase assay

For peptide assay, mTOR complex purified from 293T cells (~1000 nM) were incubated with 2 μg IRF3 peptide in the presence of 0.5 μM okadaic acid and ATP buffer (50 mM Tris-HCl, pH 7.5, 2 mM ATP, 5 mM MgCl2, 0.5 mM DTT) and incubated at 30°C for 60 minutes. The reaction mixture supernatant were then desalted and enriched using a µ-C18 Zip Tip (Millipore, ZTC18S096) and eluted directly onto an MALDI plate containing 2 mL CHCA (a-cyano-4-hydroxycinnamic acid) saturated solution in 50% acetonitrile (ACN) and 0.1% trifluoroacetic acid (TFA). MALDI-TOF spectra were acquired on a Voyager DE Promass spectrometer from Applied Biosystems.

For protein assay, mTOR complex purified from 293T cells (~1000 nM) were incubated with 2 μg GST-IRF3 in the presence of 0.5 μM okadaic acid and ATP buffer (50 mM Tris-HCl, pH 7.5, 2 mM ATP, 5 mM MgCl2, 0.5 mM DTT) and incubated at 30°C for 60 minutes. The reaction mixtures were analyzed by western blot with indicated antibodies.

In vitro acetylation assay

For FKBP12 and Rheb in vitro acetylation assay, GST-FKB12 (500 ng) or Rheb (500 ng) incubated with CBP(10 ng) in 50 mM Tris (pH7.9), 10% glycerol, 1 mM DTT, and 20 μM acetyl-CoA at 30°C for 60 min. The reaction mixtures were analyzed by western blot with indicated antibodies.
HPLC-MS/MS

To prepare samples for mass spectrometric analysis of acetylation site(s) of FKBP12 and Rheb, immunoprecipitated proteins from HEK293T cells were separated by SDS-PAGE and visualized using Coomassie blue staining. Following reduction and alkylation, in-gel digestion was performed with trypsin (Thermo Scientific, 90058) at 37°C for 16 hrs. The peptides were desalted and enriched using a μ-C18Zip Tip (Millipore) and eluted into 1% trifluoroacetic acid in 50% acetonitrile aqueous solution. The extracts were then combined and dried in a Speedvac. For LC-MS/MS analysis, the tryptic digested peptides were separated by EASY nLC 1200, and the eluted peptides were ionized and directly introduced into Orbitrap Fusion Lumos (Thermo Fisher Scientific). The data were analyzed using Proteome Discoverer 2.2.

ITC measurements

ITC (Isothermal Titration Calorimetry) experiments were performed at 20°C using MicroCalPEAQ-ITC (Malvern Panalytical Ltd, United Kingdom) for label-free solution measurements of the binding affinity (Kd) and stoichiometry (n) between rapamycin and the recombinant proteins. Rapamycin powder (Selleck, S1039) was dissolved in phosphate buffered saline (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4) containing 4.6% DMSO to final concentration of 100 μM. Protein samples were conditioned in the same buffer at final concentrations ranging from 3 to 9 μM (calculated from their UV280 nm using the sequence-estimated extinction coefficient). The integration of heats was adjusted manually. The ITC isotherm(s) were fitted using a one-site-binding model.

Microscale thermophoresis assay

A Monolith NT Automated from NanoTemper Technologies was used for MST assays. FRB, and HDAC1 proteins were fluorescently labeled with the RED-tris-NTA (MO-L008) according to the manufacturer’s instructions. SIRT2 was carried out by the LabelFree method as previously described (Soares da Costa et al., 2016). All affinity measurements were performed in PBS buffer mixed with 0.05% Pluronic F-127 (Invitrogen, P6866). Rapamycin, arrayed at different concentrations, was incubated with proteins for 30 min before application to Monolith NT standard treated capillaries. Thermophoresis was then determined at 25°C with 15-20% excitation power and middle MST power.

Immunofluorescence

The prepared cells were washed with PBS two times, then fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 10 min, then incubated in blocking buffer (3% BSA in PBS) for 1h at RT. The cells were then incubated with primary antibodies in blocking buffer overnight, washed three times, and incubated with secondary antibodies for 1h at RT. The cells were subsequently stained with 1 μg/ml Hoechst in PBS for 10 min, washed three times, and mounted with ProlongGold (Thermo Fisher Scientific). All sliders were examined using a Nikon Eclipse Ti confocal microscope.

QUANTIFICATION AND STATISTICAL ANALYSIS

Data are presented as mean ± standard deviation (SD), and statistical significance are reported in the figure legends. Statistics was analysis using Student’s t test, or analysis of variance (ANOVA) analysis (one-way ANOVA for comparisons between groups). p-values were shown on the figures as asterisks: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. Independently performed biological replicates (n values) are indicated as circles in the bar graphs.